Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

PG&E Q2 EPS $0.25 Misses $0.28 Estimate

-Reuters

byMichael Horton

July 28, 2022

1 minute read

-Reuters

Veracyte Highlights Data Presented At ASTRO 2021; Says Data Validate Prognostic Value Of Decipher Prostate Genomic Test In Newly Diagnosed, Clinically High-Risk Prostate Cancer

By Benzinga Newsdesk

Today, 6:57 AM

Veracyte, Inc. (NASDAQ:VCYT) announced today that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company's Decipher Prostate genomic classifier

VCYT

Airbus Cancels Remaining Qatar A350 Orders: Report

By Vandana Singh

Today, 6:57 AM

Airbus SE (OTC:EADSY) revoked all remaining A350 orders from Qatar Airways, raising the stakes in safety and contractual dispute…

EADSF

Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

By Vandana Singh

Today, 6:57 AM

The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…

REGN

Jaguar Health Q2 EPS $(0.12) Beats $(0.22) Estimate, Sales $2.92M Miss $3.10M Estimate

By Bill Haddad

Today, 6:57 AM

Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 60 percent increase over losses of $(0.30) per share from the

JAGX

PG&E Q2 EPS $0.25 Misses $0.28 Estimate

Related Posts

Veracyte Highlights Data Presented At ASTRO 2021; Says Data Validate Prognostic Value Of Decipher Prostate Genomic Test In Newly Diagnosed, Clinically High-Risk Prostate Cancer

Airbus Cancels Remaining Qatar A350 Orders: Report

Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis

Jaguar Health Q2 EPS $(0.12) Beats $(0.22) Estimate, Sales $2.92M Miss $3.10M Estimate